{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vinblastine",
    "query": {
      "intervention": "vinblastine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 117,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vinblastine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:53:10.570Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03912818",
      "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Mixed Adenocarcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Bladder Urothelial Carcinoma",
        "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant",
        "Infiltrating Bladder Urothelial Carcinoma With Giant Cells",
        "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation",
        "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation",
        "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Nested Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-04-10",
      "completion_date": "2022-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03912818"
    },
    {
      "nct_id": "NCT01135563",
      "title": "Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "Vinblastine and Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Hospital for Sick Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 14,
      "start_date": "2010-04",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2019-09-20",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 3,
      "location_summary": "San Diego, California • St Louis, Missouri • Burlington, Vermont",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01135563"
    },
    {
      "nct_id": "NCT00215046",
      "title": "Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intraluminal Pulmonary Vein Stenosis"
      ],
      "interventions": [
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 28,
      "start_date": "2000-03",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00215046"
    },
    {
      "nct_id": "NCT00506155",
      "title": "Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Avastin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-06",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2016-03-31",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506155"
    },
    {
      "nct_id": "NCT01404936",
      "title": "Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Interferon-2A",
          "type": "DRUG"
        },
        {
          "name": "Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "Bleomycin",
          "type": "DRUG"
        },
        {
          "name": "Velban",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "1996-07",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404936"
    },
    {
      "nct_id": "NCT04506554",
      "title": "A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "AMVAC + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2020-12-01",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 4,
      "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04506554"
    },
    {
      "nct_id": "NCT02205762",
      "title": "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Langerhans Cell Histiocytosis"
      ],
      "interventions": [
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "INDOMETHACIN",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Cytosine Arabinoside",
          "type": "DRUG"
        },
        {
          "name": "2-chlorodeoxyadenosine",
          "type": "DRUG"
        },
        {
          "name": "hematopoietic stem cell transplantation (RIC-HSCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravenous immunoglobulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "North American Consortium for Histiocytosis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 1400,
      "start_date": "2016-11-02",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02205762"
    },
    {
      "nct_id": "NCT00498979",
      "title": "Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "sodium stibogluconate",
          "type": "DRUG"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2007-05",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498979"
    },
    {
      "nct_id": "NCT06204614",
      "title": "Drug Screening Using IMD in Bladder Cancer",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Implantable Micro-Device",
          "type": "DEVICE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin I",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin II",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate/Vinblastine/Doxorubicin/Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Cisplatin/Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel/Docetaxel/Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine/Carboplatin/Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-06-14",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06204614"
    },
    {
      "nct_id": "NCT01416909",
      "title": "Managing Medication-induced Constipation in Cancer: A Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Constipation"
      ],
      "interventions": [
        {
          "name": "Laxative Treatment",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        },
        {
          "name": "Assessment Questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 601,
      "start_date": "2008-11",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-09-03T09:53:10.570Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416909"
    }
  ]
}